A pooled analysis across four clinical trials found that liver metastases are a strong negative prognostic factor for pancreatic cancer patients treated with chemotherapy, but they did not significantly alter outcomes with immune checkpoint inhibitor regimens. The result points to divergent biology or treatment sensitivity patterns depending on metastatic location and therapy class. By separating prognostic impact by treatment modality, the analysis supports a more tailored interpretation of metastatic spread when deciding between cytotoxic and immunotherapy strategies. For clinicians and trial designers, it suggests stratification by organ involvement may be more informative than using a single global prognosis metric. The immediate translational question is whether liver involvement marks chemotherapy-responsiveness limits while leaving immunotherapy unaffected, or whether sample sizes and trial designs mask smaller effects that future studies should test.